Liminal BioSciences Inc.
LMNL · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $112 | $136 | $241 | $3 |
| % Growth | -17.6% | -43.6% | 7,933.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $112 | $136 | $241 | $3 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $4,339 | $4,169 | $3,462 | $3,519 |
| G&A Expenses | $4,776 | $3,559 | $9,033 | $4,386 |
| SG&A Expenses | $4,776 | $3,559 | $3,939 | $4,386 |
| Sales & Mktg Exp. | $0 | $0 | -$5,094 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,115 | $7,728 | $7,401 | $7,905 |
| Operating Income | -$8,856 | -$7,365 | -$7,372 | -$10,353 |
| % Margin | -7,907.1% | -5,415.4% | -3,058.9% | -345,100% |
| Other Income/Exp. Net | -$119 | -$216 | $299 | $3,408 |
| Pre-Tax Income | -$8,975 | -$7,581 | -$7,073 | -$4,494 |
| Tax Expense | $166 | $67 | -$2,301 | -$33,225 |
| Net Income | -$9,141 | -$7,648 | -$4,772 | $21,915 |
| % Margin | -8,161.6% | -5,623.5% | -1,980.1% | 730,500% |
| EPS | -108.05 | -90.4 | -56.41 | 259.04 |
| % Growth | -19.5% | -60.3% | -121.8% | – |
| EPS Diluted | -2.94 | -2.46 | -1.54 | 7 |
| Weighted Avg Shares Out | 85 | 85 | 85 | 85 |
| Weighted Avg Shares Out Dil | 3,104 | 3,104 | 3,103 | 3,104 |
| Supplemental Information | – | – | – | – |
| Interest Income | $175 | $238 | $957 | $957 |
| Interest Expense | $0 | $216 | $192 | $957 |
| Depreciation & Amortization | $233 | $250 | $283 | $274 |
| EBITDA | -$8,856 | -$7,115 | -$13,704 | -$10,079 |
| % Margin | -7,907.1% | -5,231.6% | -5,686.3% | -335,966.7% |